This site is intended for healthcare professionals
News

Positive topline results from phase III trial of tislelizumab + chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer. - BeiGene

Read time: 1 mins
Last updated:24th Sep 2021
Published:22nd May 2021
BeiGene, Ltd. announced that the Phase III RATIONALE 309 trial of its anti-PD-1 antibody tislelizumab combined with chemotherapy versus placebo combined with chemotherapy as a first-line treatment for patients with recurrent or metastatic nasopharyngeal cancer (NPC) met its primary endpoint of progression-free survival (PFS) at the interim analysis, as recommended by an independent data monitoring committee.
BeiGene, Ltd. announced that the Phase III RATIONALE 309 trial of its anti-PD-1 antibody tislelizumab combined with chemotherapy versus placebo combined with chemotherapy as a first-line treatment for patients with recurrent or metastatic nasopharyngeal cancer (NPC) met its primary endpoint of progression-free survival (PFS) at the interim analysis, as recommended by an independent data monitoring committee. In the trial results, tislelizumab in combination with chemotherapy demonstrated a statistically significant improvement in PFS in the intention-to-treat (ITT) population when compared to chemotherapy alone, as assessed by an independent review committee (IRC). The safety profile of tislelizumab was consistent with its known risks, with no new safety signals identified with the addition of chemotherapy.
Condition: Nasopharyngeal Carcinoma
Type: drug